# FDA approves 1,000+ AI-enabled medical devices; most through radiology imaging

> The FDA has now cleared or approved more than 1,000 AI and machine-learning-enabled medical devices, a milestone that shows how deeply the technology has already worked its way into everyday clinical practice. The single largest category is radiology, where computer-aided detection and diagnosis tools help read scans, accounting for 75 of the 295 clearances granted in 2025 alone. Most of these devices reach the market through the 510(k) pathway, which lets a product win clearance by showing it is substantially equivalent to something already approved, rather than through lengthy new trials. That has made for a fast pipeline, but it also means much of the AI now embedded in hospitals arrived via a comparison-based process rather than fresh clinical study. The regulatory picture is still tightening. The FDA's full compliance requirements for high-risk medical-device AI do not take effect until August 2027, leaving a window in which adoption keeps racing ahead while the rules meant to govern the riskiest systems are still catching up.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: Health Law Blog · Published Tuesday, August 25, 2026_

## Wortins' read

The FDA has now cleared or approved more than 1,000 AI and machine-learning-enabled medical devices, a milestone that shows how deeply the technology has already worked its way into everyday clinical practice. The single largest category is radiology, where computer-aided detection and diagnosis tools help read scans, accounting for 75 of the 295 clearances granted in 2025 alone. Most of these devices reach the market through the 510(k) pathway, which lets a product win clearance by showing it is substantially equivalent to something already approved, rather than through lengthy new trials. That has made for a fast pipeline, but it also means much of the AI now embedded in hospitals arrived via a comparison-based process rather than fresh clinical study. The regulatory picture is still tightening. The FDA's full compliance requirements for high-risk medical-device AI do not take effect until August 2027, leaving a window in which adoption keeps racing ahead while the rules meant to govern the riskiest systems are still catching up.

## Source

[Read the full story at Health Law Blog](https://healthlawblog.dwlaw.com/2026/08/the-state-of-ai-regulation-in-healthcare-still-complicated/)

## Related coverage

- [ShepHertz Launches AgentAnywhere, Sovereign Agentic AI Platform for Regulated Industries](https://www.wortins.com/story/shephertz-launches-agentanywhere-sovereign-agentic-ai-platfo-a80b8050) — [ShepHertz](https://aiagentstore.ai/ai-agent-news/this-week)
- [Google Cloud Launches Gemini Enterprise for Financial Services](https://www.wortins.com/story/google-cloud-launches-gemini-enterprise-for-financial-servic-5d0fd141) — [Google Cloud](https://www.googlecloudpresscorner.com/2026-08-25-Google-Cloud-Launches-Gemini-Enterprise-for-Financial-Services)
- [Cohere Launches Command A+ Mixture-of-Experts Model](https://www.wortins.com/story/cohere-launches-command-a-mixture-of-experts-model-5d840970) — [Cohere](https://docs.cohere.com/docs/command-a-plus)
- [OpenAI Expands Daybreak With GPT-5.6-Cyber Cybersecurity Model](https://www.wortins.com/story/openai-expands-daybreak-with-gpt-5-6-cyber-cybersecurity-mod-9f70603c) — [TechCrunch](https://techcrunch.com/2026/08/10/as-ai-led-attacks-multiply-openai-launches-a-new-cyber-model/)
- [Agents Over Bubbles](https://www.wortins.com/story/agents-over-bubbles-3e7bd726) — [Stratechery](https://stratechery.com/2026/agents-over-bubbles/)
- [Alibaba Raises $10.2 Billion in Record Hong Kong Share Sale to Fund AI Expansion](https://www.wortins.com/story/alibaba-raises-10-2-billion-in-record-hong-kong-share-sale-t-ee1afa0a) — [Bloomberg](https://www.bloomberg.com/news/articles/2026-08-23/alibaba-to-raise-10-billion-by-selling-shares-for-ai-expansion)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._